Test Your HIV Management Skills Across the Spectrum of Care
Clinical Practice Guidelines
Guidelines for the primary and gender-affirming care of transgender and gender nonbinary people.
Deutsch MB, eds. University of California San Francisco.
Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the International Antiviral Society–USA panel.
Saag MS, Gandhi RT, Hoy JF, et al. JAMA. 2020;324(16):1651-1669.
Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV.
US Department of Health and Human Services
Clinical Resources
Adult Immunization Schedule.
Centers for Disease Control and Prevention.
Patient Health Questionnaire-9 (PHQ-9).
National HIV Curriculum
North America Syringe Exchange Network.
Recommendation Topics.
United States Preventive Services Task Force.
Patient and Caregiver Resources
AIDSMap Resources
NAM Publications
Resources for persons living with HIV
Centers for Disease Control and Prevention
HIV resources
National Institutes of Health
Behavioral Health Treatment Services Locator
Substance Abuse and Mental Health Services Administration
Suggested Readings
Antiretroviral therapy for the prevention of HIV-1 transmission.
Cohen MS, Chen YQ, McCauley M, et al. N Engl J Med. 2016;375(9):830-839.
Implementation of a rapid entry program decreases time to viral suppression among vulnerable persons living with HIV in the southern United States.
Colasanti J, Sumitani J, Mehta CC, et al. Open Forum Infect Dis. 2018;5(6):ofy104.
Risk of cardiovascular disease associated with exposure to abacavir among individuals with HIV: A systematic review and meta-analyses of results from 17 epidemiologic studies.
Dorjee K, Choden T, Baxi SM, et al. Int J Antimicrob Agents. 2018;52(5):541-553.
Characteristics, prevention, and management of cardiovascular disease in people living with HIV: a scientific statement from the American Heart Association.
Feinstein MJ, Hsue PY, Benjamin LA, et al. Circulation. 2019;140(2):e98-e124.
Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study.
Friis-Møller N, Weber R, Reiss P, et al. AIDS. 2003;17(8):1179-1193.
Linkage and antiretroviral therapy within 72 hours at a Federally Qualified Health Center in New Orleans.
Halperin J, Butler I, Conner K, et al. AIDS Patient Care STDS. 2018;32(2):39-41.
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in a rapid-initiation model of care for human immunodeficiency virus type 1 infection: Primary analysis of the DIAMOND study.
Huhn GD, Crofoot G, Ramgopal M, et al. Clin Infect Dis. 2020;71(12):3110-3117.
Initiation of antiretroviral therapy in early asymptomatic HIV infection.
INSIGHT START Study Group, Lundgren JD, Babiker AG, et al. N Engl J Med. 2015;373(9):795-807.
The effect of same-day observed initiation of antiretroviral therapy on HIV viral load and treatment outcomes in a US public health setting.
Pilcher CD, Ospina-Norvell C, Dasgupta A, et al. J Acquir Immune Defic Syndr. 2017;74(1):44-51.
Global burden of atherosclerotic cardiovascular disease in people living with HIV: Systematic review and meta-analysis.
Shah ASV, Stelzle D, Lee KK, et al. Circulation. 2018;138(11):1100-1112.
An Immersive Patient and Provider Simulation
Relevant Resources
The PCPs Role in Preventing HIV
What Do You Know About PrEP?
Optimizing Use of Clinical Evidence & Pharmacoeconomic Models in Managed Care
What Do You Know About PrEP?
Got it? Treat it!
The Critical Role of the Community Pharmacist
Bringing Local Communities Together to Eliminate Coinfection Through Knowledge and Partnerships.
Volume 1: Rapid ART Initiation: A New Addition to the HIV-Care Tool Box
Key Issues Impacting OB/GYN Practice
Hot Topics in HBV, HCV, and NASH
Volume II: Expanding Evidence for the Role of Rapid ART Initiation in HIV Practice
Why It Matters in OB/GYN Practice Today
A Treater’s Guide to Optimizing Care in the Aging Patient with Comorbidities
How the Pharmacist Can Make a Difference
HIV Can Be Prevented— Are You Doing Your Part?
Rapid Start ART — A New Model for HIV Care
Understanding the Growing Syndemic — Opioids, HCV, and HIV
A PrEP Primer
The PCP’s Role in HCV Elimination
What the Pharmacist Needs to Know about PrEP
The Rapid ART Standard of Care: From Evidence to Healthcare Equity
Maximizing Your Role to Impact Patient Outcomes
Building Bridges to Reach People Who Inject Drugs With the Goal to Eliminate HCV
Benefits, Barriers, & Best Practices in an Advancing Field
Practical Solutions Across the Spectrum of Care
A PEP/PrEP Training Guide for Pharmacists
A Critical Step Toward HCV Elimination
Considering the Patient, the Provider, and the Science
A Multidisciplinary Online Mini-Curriculum
Debates and Discussions about Monoclonal Antibody Therapies
An Update on Monoclonal Antibody Therapies
Establishing Clinical Readiness Through Mentored Learning
Recent Developments in Anti-SARS-CoV-2 Monoclonal Antibodies for Treatment
An Update on Best Practices
New Avenues to Pre-Exposure Prophylaxis
An Updated Clinician’s Guide to Assessment and Management
What the Pharmacist Needs to Know
A Look at the Changing HIV Playing Field
A “How To” Series Spanning Policy to Practice
Test Your Mastery!
Building Bridges to Reach People who Inject Drugs with the Goal of Employing PrEP for HIV Prevention
Bringing HIV Prevention to a New Level
Optimizing HIV Prevention in Primary Care
Monoclonal Antibodies for the Prevention and Treatment of COVID-19
A Phone-a-Friend CME Series – Volume 2
Incorporating New Data and Updated Guidelines Into Daily Practice
